Focus

Therapeutics Investors: Angels and VC Firms

The RaiseHunt database lists 4,956 Therapeutics investors: 410 angel investors and 4,546 people at 870 firms. Most list Seed and Series A among their stages; the largest hubs are New York, San Francisco and Boston.

Strongest in New York, San Francisco and Boston

Common stages: Seed and Series A

4,956
Therapeutics investors
410
Angel investors
4,546
People at VC/PE firms
870
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

4,956 Therapeutics investors

Showing 1-20

Filters
Atherton, United States
AngelOperator angel
AIHealthcare
View profile
Chicago, United States
Angel
ConsumerHealthcare
View profile
Seattle, United States
AngelOperator angel
AIClimate
View profile
Dennis Purcell
Dennis Purcell

Founder and Senior Advisor

New York, United States
Angel
Healthcare
View profile
Anton Neschadim
Anton Neschadim

Venture Capital, Senior Advisor

Toronto, Canada
AngelOperator angel
AIHealthcare
View profile
Iowa City, United States
Angel
EnergyFinTech
View profile
Philadelphia, United States
Angel
AIFinTech
View profile
Michael Jin
Michael Jin

Managing Partner

Palo Alto, United States
AngelOperator angel
AIClimate
View profile
Bart Markus
Bart Markus

Fund Advisor and member of ICOM

Munich, Germany
AngelOperator angel
AIEnergy
View profile
Eric Hippeau
Eric Hippeau

Managing Partner

New York, United States
Angel
ConsumerFinTech
View profile
Anthony Goldbloom
Anthony Goldbloom

Investment Partner

San Francisco, United States
AngelOperator angel
AICommerce
View profile
Stephan von Perger
Stephan von Perger

Startup Partnerships

Berlin, Germany
AngelOperator angel
AIHealthcare
View profile
New York City, United States
Angel
ConsumerHealthcare
View profile
Margo Georgiadis
Margo Georgiadis

Managing Partner

San Francisco, United States
AngelOperator angel
AIHealthcare
View profile
John Leonard
John Leonard

Board Member

Cambridge, United States
Angel
AIHealthcare
View profile
Dov Moran
Dov Moran

Managing Partner

Israel
Angel
AIClimate
View profile
San Francisco, United States
Angel
AIHardware
View profile
Evan Schwartz
Evan Schwartz

Board Observer

Boston, United States
AngelOperator angel
AIHealthcare
View profile
New York, United States
AngelOperator angel
ConsumerFinTech
View profile
Jay Kapoor
Jay Kapoor

General Partner

United States
AngelOperator angel
AIClimate
View profile

900 of 4,956 Therapeutics investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A90

B30

C56

D56

E25

F17

G22

H20

I15

J134

K41

L30

M94

N16

O7

P36

Q4

R50

S68

T40

U1

V14

W13

X1

Y9

Z11

Frequently asked questions

How many Therapeutics investors are on RaiseHunt?

RaiseHunt currently lists 4,956 Therapeutics investors.

Are Therapeutics investors angels or funds?

Both. 410 are angel investors putting in their own money, and 4,546 are people making investment decisions at 870 firms.

Where are most Therapeutics investors based?

The largest concentrations are in New York, San Francisco and Boston.

What stage do Therapeutics investors invest at?

Most list Seed and Series A among the rounds they take part in.

How do I contact Therapeutics investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Therapeutics investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Therapeutics investors only back Therapeutics companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

What should I have ready before reaching out?

A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Investors read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.

Does a warm introduction still matter?

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

How do I know which Therapeutics investors are a fit?

Look at what they have already funded rather than what their profile says they like. Stage matters most, then sector, then geography. An investor who has never funded anything at your stage is unlikely to start with you, however well the sector lines up.

How long does raising a round usually take?

Longer than most first-time founders plan for. The work splits into building the list, running outreach, taking meetings, and closing, and each stage can stretch. Start before you need the money, not when the runway is short.

What do investors look at first?

The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.

Data: RaiseHunt investor dataset · Snapshot 26 September 2026 · How this data is built · Report a correction or request removal